Señales en vivo de IVA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	52 094.00
Volumen promedio	41 918.00
Capitalización de mercado	179.63M
EPS	$0 ( 2024-04-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.320
ATR14	$0.0630 (1.84%)

Inventiva S.A. Correlación

10 Correlaciones Más Positivas
CPIX	0.937
PSTX	0.933
SRTS	0.931
NESR	0.93
TKNO	0.926
ENTA	0.924
GTEC	0.923
FULC	0.921
CNDT	0.916
MULN	0.915

10 Correlaciones Más Negativas
XOG	-0.895
VERX	-0.894
HSTM	-0.878
BOCH	-0.868
EPZM	-0.864
CNCE	-0.86
HURN	-0.858
FIZZ	-0.854
IMRX	-0.852
MXIM	-0.847

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inventiva S.A. Finanzas

Annual	2023
Ingresos:	$17.48M
Beneficio Bruto:	$17.50M (100.13 %)
EPS:	$-2.43

FY	2023
Ingresos:	$17.48M
Beneficio Bruto:	$17.50M (100.13 %)
EPS:	$-2.43

FY	2022
Ingresos:	$12.18M
Beneficio Bruto:	$11.18M (91.83 %)
EPS:	$-1.310

FY	2021
Ingresos:	$4.19M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.270

Financial Reports:

Symbol	Period	Year	Title
IVA	FY	2023	Inventiva S.A. Reports Fiscal Year 2023 Financial Results

Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.